NINLARO(ixazomib capsules) UK Website

 

NINLARO is licensed in combination with lenalidomide and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.

This website has been developed by Takeda Oncology and contains product and prescribing information intended for UK healthcare professionals. In addition, the site contains specific information for patients prescribed NINLARO. General information on multiple myeloma for the general public is also included.

Please select the appropriate option below to continue:

I am a UK Healthcare ProfessionalI have been prescribed NINLAROI am a member of the public

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.

Reporting of side effects

Ninlaro (ixazomib) and Revlimid (lenalidomide) are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects whilst taking the Ninlaro regimen, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the package leaflets. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of these medicines.

Takeda Oncology, Takeda and NINLARO are registered trademarks of Takeda Pharmaceutical Company Limited.

REVLIMID is a registered trademark of Celgene Corporation. Other trademarks are the property of their respective owners.

© Takeda UK Limited, 2017

Registered office: Takeda UK Limited, Building 3, Glory Park, Glory Park Avenue, Wooburn Green, Bucks, HP10 0DF

Registered in England and Wales No. 3362860

UK/IXA/1611/0088a - Jan 2017

Takeda Oncology

External link

The link you have selected is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.

Please confirm you wish to follow this link.